Monograph Details
|
|
Dermatological Disorders
> Miscellaneous dermatological conditions
|
|
SOLAGE |
| Manufacturer |
|
Barrier Therapeutics |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Depigmenting agent. |
| Generic Name |
|
Mequinol 2%, tretinoin 0.01%; topical soln; contains alcohol 77.8%. |
| Indications |
|
Treatment of solar lentigines, as an adjunct to skin care and sun avoidance. |
| Children |
|
Not recommended. |
| Adults |
|
Apply twice daily (8 hours apart); avoid normal skin. Allow at least 30 minutes before applying cosmetics and at least 6 hours before washing area. |
| Contraindications |
|
Women of childbearing potential. Pregnancy (Cat.X). |
| Precautions |
|
Do not use on sunburn, eczema, other inflamed or irritated chronic skin conditions. Reduce dose or discontinue if excessive irritation occurs; discontinue if sensitivity or systemic adverse reaction occurs. Sun sensitivity. Avoid sun, UV light, eyes, mouth, paranasal creases, mucous membranes. Non-Caucasians, moderately or heavily pigmented skin (skin type VI). Vitiligo (or family history thereof). Weather extremes (eg, wind, cold). Product is flammable. Nursing mothers. |
| Interactions |
|
Do not use with photosensitizers (eg, thiazides, tetracyclines, quinolones, phenothiazines, sulfonamides). Avoid concomitant topical drugs, medicated/abrasive soaps, shampoos, cleansers, cosmetics with a strong drying effect, products with high alcohol content, astringents, spices or lime, permanent wave solns, electrolysis, depilatories or waxes, or other skin irritants. |
| Adverse Reactions |
|
Erythema, burning, stinging, tingling, desquamation, pruritus, irritation, hypopigmentation, photosensitivity, vesicular bullae. |
| How Supplied |
|
Soln—30mL |
|
|
|
|
